Genetic Testing Could Identify HIV Patients At Risk Of Hypersensitivty To HIV Drug
HIV patients at risk of a potentially fatal hypersensitive reaction to the antiretroviral drug abacavir could be identified by genetic testing before drug therapy has started, suggest authors of a fast-track study in this week’s issue of THE LANCET.
The use of the HIV antiretroviral drug abacavir, a potent HIV-1 nucleoside-analogue reverse-transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases. Genetic factors influencing the immune response to abacavir might result in some individuals being more susceptible to a hypersensitive reaction than other patients.
Simon Mallal and colleagues from the Royal Perth Hospital, Australia, studied 200 HIV patients treated with abacavir. They focused on analysis of the MHC genes that are known to be associated with the immune response.
Abacavir hypersensitivity was identified in 18 patients, and drug tolerance was confirmed in 167 patients after 6 weeks of therapy. Patients with the allele (gene component) HLA-B*5701 were over 100 times more likely to be hypersensitive to abacavir; this allele was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir-tolerant patients. The genetic region marked by the combination HLA-B*5701, HLA-DR7, and HLA-DQ3 (the 57.1 ancestral haplotype) was present in 13 (72%) hypersensitive patients and none of the tolerant patients. All patients with the full 57.1 ancestral haplotype experienced abacavir hypersensitivity.
Simon Mallal comments: “The findings have important clinical implications. In our population, withholding abacavir in patients with this haplotype would be expected to reduce the prevalence of this potentially life-threatening event from 9% to 2.5 % without inappropriately denying the drug to any patients. Based on these data it is our current practice to withhold abacavir in patients who have the HLA-B*5701,-DR7,-DQ3 haplotype. However, before such practice can be taken up by others it is essential that the association between HLA type and abacavir hypersensitivity in their own populations is assessed.”
He adds: “However, there were four patients in the study who developed abacavir hypersensitivity in whom no part of the susceptibility haplotype could be identified. Therefore, HLA typing at these alleles could not be used to completely exclude the risk of a future reaction, and the current clinical approach of high vigilance for these reactions must continue.”
In an accompanying Commentary (p 722), Amalio Telenti from University Hospital, Lausanne, Switzerland,concludes: “From recent developments in human genetics, a need for a more comprehensive analysis, including dozens or hundreds of genes, can be predicted. This analysis may become feasible by use of microarrays that allow interrogation of multiple genes simultaneously. Decisions about the best time to start therapy, and the most effective and least toxic drug combinations, may be based on particular genotype profiles. This projection may look far-fetched, with just a few relevant genes identified, but these are the first drops before a downpour.”
Richard Lane | alphagalileo
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Mapping the interaction of a single atom with a single photon may inform design of quantum devices
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...